Estimaciones de analistas de Wall Street para Fortress Biotech, Inc. (FBIO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 6 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 6 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-16 | $-0.27 | ||
| 2026-08-13 | $-0.08 | $-0.20 | +60.0% |
| 2026-05-14 | $2.82 | $-0.22 | +1381.8% |
| 2026-03-31 | $-0.21 | $0.42 | -150.0% |
| 2025-11-14 | $0.11 | $-0.43 | +125.6% |
| 2025-08-14 | $-0.46 | $-0.31 | -48.4% |
| 2025-05-15 | $-0.48 | $-0.44 | -9.1% |
| 2025-03-31 | $-0.26 | $-0.79 | +67.1% |
Ratios de valoración
| Ratio P/E | 0.75 |
| Precio / Valor contable | 0.47 |
| EV / EBITDA | -4.81 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $16.5M | $187.6M | $26.9M | $36.6M | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Coste de Ventas | $11.3M | $161.2M | $6.1M | $10.5M | $14.6M | $32.1M | $30.8M | $22.9M | $20.9M | $20.9M |
| Beneficio Bruto | $5.1M | $26.4M | $20.8M | $26.1M | $31.0M | $36.7M | $45.0M | $61.6M | $36.8M | $42.3M |
| I+D | $35.1M | $52.5M | $87.4M | $81.3M | $64.1M | $128.9M | $134.9M | $106.1M | $56.9M | $11.9M |
| Generales y Administrativos | $32.9M | $73.0M | $53.4M | $55.6M | $61.2M | $86.8M | $113.7M | $91.0M | $87.7M | $96.4M |
| Gastos Operativos | $70.8M | $127.6M | $140.8M | $136.9M | $125.3M | $225.2M | $248.5M | $204.0M | $147.2M | $112.6M |
| Beneficio Operativo | -$65.7M | -$89.8M | -$120.0M | -$110.8M | -$94.3M | -$188.5M | -$203.6M | -$142.3M | -$110.4M | -$70.2M |
| EBITDA | -$66.9M | -$88.6M | -$118.4M | -$88.5M | -$87.8M | -$146.2M | -$193.7M | -$135.7M | -$104.5M | -$20.2M |
| Gastos por Intereses | $3.7M | $7.7M | $10.3M | $11.8M | $15.3M | $15.3M | $13.6M | $12.5M | $9.9M | $8.7M |
| Beneficio Antes de Impuestos | -$71.3M | -$98.3M | -$130.8M | -$101.7M | -$102.8M | -$164.4M | -$213.5M | -$153.6M | -$120.5M | -$33.5M |
| Impuestos | 0 | $1.5M | -$463000 | 0 | $136000 | $473000 | $449000 | $521000 | $312000 | -$620000 |
| Beneficio Neto | -$55.1M | -$66.9M | -$84.1M | -$40.0M | -$46.5M | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.8M |
| BPA | $-20.68 | $-24.08 | $-29.04 | $-10.95 | $-9.75 | $-11.85 | $-14.55 | $-8.47 | $-2.69 | $-0.07 |
| BPA Diluido | $-20.68 | $-24.08 | $-29.04 | $-10.95 | $-9.75 | $-11.85 | $-14.55 | $-8.47 | $-2.69 | $-0.05 |
| Acciones en Circulación (Diluidas) | $2.7M | $2.8M | $2.9M | $3.6M | $4.8M | $5.4M | $5.9M | $8.1M | $20.8M | $35.8M |
Precio
| Precio | $2.46 |
| Capitalización | $82M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADAG · CRVO · GANX · IMUX · NTRB · PMVP · RLMD
Explorar sector: Healthcare · Biotechnology
Más secciones de FBIO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones